Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 24560135)

1.

The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.

Black RN, Ennis CN, Young IS, Hunter SJ, Atkinson AB, Bell PM.

J Diabetes Complications. 2014 May-Jun;28(3):323-7. doi: 10.1016/j.jdiacomp.2014.01.001. Epub 2014 Jan 8.

PMID:
24560135
2.

Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.

Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q.

Br J Pharmacol. 2009 Oct;158(3):706-12. doi: 10.1111/j.1476-5381.2009.00350.x. Epub 2009 Aug 19.

3.

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.

Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, Gomez EV, Russo JM.

JAMA. 2007 Mar 28;297(12):1362-73. Epub 2007 Mar 25.

PMID:
17384435
4.

Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.

Anderlová K, Dolezalová R, Housová J, Bosanská L, Haluzíková D, Kremen J, Skrha J, Haluzík M.

Physiol Res. 2007;56(5):579-86. Epub 2006 Dec 19.

5.

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.

PMID:
17520238
7.

Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.

Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA.

Atherosclerosis. 2004 Aug;175(2):325-31.

PMID:
15262189
8.

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.

Belfort R, Berria R, Cornell J, Cusi K.

J Clin Endocrinol Metab. 2010 Feb;95(2):829-36. doi: 10.1210/jc.2009-1487. Epub 2010 Jan 8.

9.

Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.

Huptas S, Geiss HC, Otto C, Parhofer KG.

Am J Cardiol. 2006 Jul 1;98(1):66-9. Epub 2006 May 4.

PMID:
16784923
10.

Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.

Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):805-13. doi: 10.5414/CP201735.

PMID:
22943927
11.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1420. Lancet. 2006 Oct 21;368(9545):1415.

PMID:
16310551
12.
13.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

14.

Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.

Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.

Diabet Med. 2010 Feb;27(2):150-6. doi: 10.1111/j.1464-5491.2009.02906.x.

PMID:
20546257
16.

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.

Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK.

J Am Coll Cardiol. 2010 Mar 23;55(12):1209-16. doi: 10.1016/j.jacc.2009.10.053.

17.

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J.

Cardiovasc Res. 2001 Nov;52(2):290-8.

18.

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Feb;57(2):246-54. doi: 10.1016/j.metabol.2007.09.008.

PMID:
18191056
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk